PAR 2.56% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3191

  1. 1,585 Posts.
    lightbulb Created with Sketch. 632
    Yes thanks for this!
    The Kraus talk looked like a key one, youtube link below. In it she actualy says around 12 minutes...."Biomarkers DO exist....that are reasonably likely to predict importnant benefits to patients", and pointing to the AD aducanumab approval as a precedent that should pave the way for an Accelerated Approval in OA. Just wow.




 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.